HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.

AuthorsMakoto Tanaka, Hiroshi Mori, Kiyoshi Shimizu, Toshiyuki, Matsuoka, Hajime Yamamotoya, Toshiomi Minamide, Masamichi Mori, Kazutoshi Nozaki, Takashi Usui, Kenichiro Shimokawa, Hiromi Suzuki, Koji Aoyama, Aishi Kimoto, Masao Sasamata, Keiji Miyata
JournalNihon yakurigaku zasshi. Folia pharmacologica Japonica (Nihon Yakurigaku Zasshi) Vol. 134 Issue 3 Pg. 149-57 (09 2009) ISSN: 0015-5691 [Print] Japan
PMID19749488 (Publication Type: Journal Article, Review)
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • YM 529
  • Geranyltranstransferase
  • GTP-Binding Proteins
  • Mevalonic Acid
Topics
  • Animals
  • Bone Density (drug effects)
  • Bone Density Conservation Agents (administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
  • Bone Remodeling (drug effects)
  • Bone Resorption (drug therapy)
  • Clinical Trials as Topic
  • Diphosphonates (administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
  • GTP-Binding Proteins (metabolism)
  • Geranyltranstransferase (antagonists & inhibitors)
  • Humans
  • Imidazoles (administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
  • Mevalonic Acid (metabolism)
  • Osteoporosis (drug therapy)
  • Spinal Fractures (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: